Nuveen
XFOR icon

Nuveen’s X4 Pharmaceuticals XFOR Stock Holding History

Nuveen’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$502K Buy
+107,389
New +$441K ﹤0.01% 3268
2024
Q4 		– Sell
-16,625
Closed -$334K – 3346
2024
Q3 		$334K Hold
16,625
– – ﹤0.01% 3125
2024
Q2 		$289K Buy
16,625
+2,021
+14% +$66.1K ﹤0.01% 3160
2024
Q1 		$609K Hold
14,604
– – ﹤0.01% 2909
2023
Q4 		$367K Hold
14,604
– – ﹤0.01% 3099
2023
Q3 		$478K Hold
14,604
– – ﹤0.01% 2857
2023
Q2 		$850K Buy
+14,604
New +$750K ﹤0.01% 2724
2021
Q2 		– Sell
-2,670
Closed -$689K – 3552
2021
Q1 		$689K Sell
2,670
-138
-5% -$36.3K ﹤0.01% 3012
2020
Q4 		$541K Buy
2,808
+38
+1% +$7.46K ﹤0.01% 3026
2020
Q3 		$562K Buy
2,770
+14
+0.5% +$3.36K ﹤0.01% 2915
2020
Q2 		$771K Buy
2,756
+1,294
+89% +$354K ﹤0.01% 2731
2020
Q1 		$439K Buy
1,462
+389
+36% +$110K ﹤0.01% 2813
2019
Q4 		$344K Hold
1,073
– – ﹤0.01% 2978
2019
Q3 		$409K Buy
1,073
+679
+172% +$269K ﹤0.01% 2999
2019
Q2 		$177K Buy
+394
New +$200K ﹤0.01% 3191

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nuveen's XFOR Position: Q2 2026 in Review

Nuveen opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 107,389 shares worth $502K. The stake represents ﹤0.01% of the portfolio and ranks #3268 among its holdings. This is a return to the name: Nuveen previously reported a position in XFOR as recently as Q3 2024.

Nuveen first reported a position in XFOR in Q2 2019 and has held it in 15 quarters since. The position peaked at $850K in Q2 2023. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Nuveen held 107,389 shares of X4 Pharmaceuticals worth $502K as of Q2 2026.
  • X4 Pharmaceuticals was a new Nuveen position in Q2 2026.
  • X4 Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3268 holding.
  • Nuveen first reported a position in X4 Pharmaceuticals in Q2 2019 and has held it in 15 quarters since.
  • Nuveen's X4 Pharmaceuticals position peaked at $850K in Q2 2023.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.